Gestational diabetes mellitus (GDM) is a growing concern for pregnant women and their healthcare providers. This condition poses significant risks to both the mother and the developing fetus, making early detection and management crucial. However, the current biomarkers used for GDM screening have limitations, leaving a gap in our ability to accurately assess and address this issue.
In this study, we aimed to delve deeper into the relationship between plasma transthyretin (TTR) concentrations and the development of GDM, as well as the interaction between TTR and maternal body mass index (BMI) on the risk of GDM across different trimesters of pregnancy.
Our research involved a retrospective cohort study of 12,893 pregnant women from the Second Affiliated Hospital of Wenzhou Medical University. We utilized multivariate restricted cubic spline (RCS) models and logistic regression to analyze the connection between TTR concentrations, maternal BMI, and the risk of GDM.
The findings revealed significant differences in TTR concentrations between the GDM and non-GDM groups in the first and third trimesters. Interestingly, as pregnancy progressed, TTR concentrations gradually decreased in the GDM group. In the first and second trimesters, we observed that the risk of GDM increased with rising TTR concentrations, and this risk was further amplified when combined with an overweight status.
In the third trimester, a unique reverse "J"-shaped nonlinear relationship was noted between TTR concentrations and GDM risk. Here, the combination of a higher BMI and lower TTR concentrations significantly increased the risk, indicating a positive interaction on the multiplicative scale.
These results suggest that elevated TTR concentrations in the first trimester and lower concentrations in the third trimester are linked to a higher risk of GDM. Moreover, the combination of high TTR concentrations and high BMI appears to exacerbate this risk, highlighting the potential of TTR as a valuable biomarker for early detection and risk assessment of GDM.
Our study provides valuable insights into the complex interplay between TTR, BMI, and GDM risk. However, it's important to note that further research is needed to fully understand the underlying mechanisms and the potential clinical applications of these findings.
As we continue to unravel the mysteries of GDM, we encourage open dialogue and further exploration of these intriguing results. Do you think TTR could be a game-changer in GDM screening and management? Share your thoughts and let's spark a conversation!
